Fundraising Fox
/Companies
Sign in

attivare

Natick, US · Founded 2020 · 8 known investors

Find your way into attivare

Sign up to see every warm intro you have to attivare

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the attivare team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Attivare develops AI-powered personalized immunotherapy treatments using a proprietary biomaterial scaffold (ATTImmune) that delivers immune agonists directly to tumor microenvironments, aiming to reduce systemic toxicity in cancer and infectious disease treatment.

AI & Machine LearningBiotechMedical Devices

Founders & leadership

ED
Edward DohertyNamed on SEC filing
JM
Jessica McDonoughNamed on SEC filing
JTJoaquim Trias
Joaquim TriasNamed on SEC filing

Board

ZMZeshan Muhammedi
Zeshan MuhammediMember, Board of Directors2021–2024Managing Partner at MBX Capital

Investors · 8

Divergent Capitallisted by Divergent CapitalNew York · $250K – $1M

How we know: Divergent Capital's portfolio page · Not right? Tell us

Embark Ventureslisted by Embark VenturesLos Angeles

How we know: Embark Ventures's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Harmonix Fundlisted by Harmonix FundLa Quinta

How we know: Harmonix Fund's portfolio page · a partner's Signal profile · Not right? Tell us

Mana Ventureslisted by Mana VenturesEstero
MBX Capitallisted by MBX CapitalClaymont · $250K – $2.5M

How we know: MBX Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Ulu Ventureslisted by Ulu VenturesPalo Alto · $2M

How we know: Ulu Ventures's portfolio page · Not right? Tell us

Axial VCreportedSan Francisco · $100K – $5M

How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$5.9M disclosed across 1 round · 2021

▶$5.9MraisedDec 2021 · 23 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward DohertyExecutive Officer
  • Jessica McDonoughDirector
  • Zeshan MuhammediDirector
  • Joaquim TriasExecutive Officer, Director
Offering amount
$7.8M
Amount sold
$5.9M
First sale
Aug 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

Avilar TherapeuticsAvilar develops ATACs (ASGPR Targeting Chimeras), a class of protein degraders designed to target extracellular and membrane-bound proteins by harnessing the endolysosome's natural degradation process. The company applies its drug discovery platform to create degraders as potential treatments for serious diseases.
Atara BiotherapeuticsAtara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease. The company focuses on next-generation cell-based therapies designed for patients worldwide.
Arvinas Holding Co. LLCArvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology. It advances preclinical research into clinical-stage treatments for patients with limited or ineffective existing options.
VeratxVera Therapeutics develops medicines targeting autoimmune-driven kidney diseases, with a focus on reducing the need for dialysis or transplant. The company was founded by a physician and operates as a clinical-stage biotech with a patient-centered approach to drug development.
Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.

Companies working in the same space as attivare.

Frequently asked questions

What does attivare do?
Attivare develops AI-powered personalized immunotherapy treatments using a proprietary biomaterial scaffold (ATTImmune) that delivers immune agonists directly to tumor microenvironments, aiming to reduce systemic toxicity in cancer and infectious disease treatment.
Who are attivare's investors?
attivare's investors include AAF Management Ltd., Divergent Capital, Embark Ventures, Harmonix Fund, Mana Ventures, MBX Capital, Ulu Ventures, Axial VC.
How much funding has attivare raised?
attivare has disclosed $5.9M raised across 1 round.
Where is attivare headquartered?
attivare is headquartered in Natick, US.